Journal: Frontiers in Oncology

Article Title: Evaluation of Microwave Ablation in 4T1 Breast Tumor by a Novel VEFGR2 Targeted Ultrasound Contrast Agents

doi: 10.3389/fonc.2021.690152

Figure Lengend Snippet: Characteristic of NPs. (A, B) TEM and diameter distribution image of Fe-HSNs. (C) LSCM images of VEGFR2-PEG-HSNs-Fe. VEGFR2-PEG-HSNs-Fe modified with luciferin PE by laser excitation showed red fluorescence.

Article Snippet: Anti-VEGFR2/KDR antibody and P-phycoerythrin (PE)-conjugated rabbit antimouse VEGFR2 monoclonal antibody were obtained from Sino Biological (Beijing, China).

Techniques: Modification, Fluorescence

Journal: Frontiers in Oncology

Article Title: Evaluation of Microwave Ablation in 4T1 Breast Tumor by a Novel VEFGR2 Targeted Ultrasound Contrast Agents

doi: 10.3389/fonc.2021.690152

Figure Lengend Snippet: (A) US images of VEGFR2-PEG-HSNs-Fe with different concentrations; (B) signal intensity of VEGFR2-PEG-HSNs-Fe with different concentrations in CEUS mode.

Article Snippet: Anti-VEGFR2/KDR antibody and P-phycoerythrin (PE)-conjugated rabbit antimouse VEGFR2 monoclonal antibody were obtained from Sino Biological (Beijing, China).

Techniques:

Journal: Frontiers in Oncology

Article Title: Evaluation of Microwave Ablation in 4T1 Breast Tumor by a Novel VEFGR2 Targeted Ultrasound Contrast Agents

doi: 10.3389/fonc.2021.690152

Figure Lengend Snippet: (A) Western-blot images and quantitative analysis (B) of VEGFR2 membrane protein expression in HUVEC and 4T1 cells. (C) Confocal microscope images of HUVEC and 4T1 cells incubation with VEGFR2-PEG-HSNs-Fe. (D) FCM images of HUVEC and 4T1 cells in different groups (simple cells, targeted competition, non-targeted and targeted groups).

Article Snippet: Anti-VEGFR2/KDR antibody and P-phycoerythrin (PE)-conjugated rabbit antimouse VEGFR2 monoclonal antibody were obtained from Sino Biological (Beijing, China).

Techniques: Western Blot, Expressing, Microscopy, Incubation

Journal: Frontiers in Oncology

Article Title: Evaluation of Microwave Ablation in 4T1 Breast Tumor by a Novel VEFGR2 Targeted Ultrasound Contrast Agents

doi: 10.3389/fonc.2021.690152

Figure Lengend Snippet: (A) FCM images of HUVEC and 4T1 cells at different concentrations of VEGFR2-PEG-HSNs-Fe (50, 100, 200 μg/ml) and PBS for 24 h. (B) Heat map of main serum immune factors in nude mice with breast tumor injected with VEGFR2-PEG-HSNs-Fe at different time (0, 0.5, 1, 12, 24). (C) Immunofluorescence staining images of 4T1 tumor tissue slices (magnification: ×400). CD31 was labeled by red fluorescence, VEGFR2 by green fluorescence, and tumor nucleus by blue fluorescence.

Article Snippet: Anti-VEGFR2/KDR antibody and P-phycoerythrin (PE)-conjugated rabbit antimouse VEGFR2 monoclonal antibody were obtained from Sino Biological (Beijing, China).

Techniques: Injection, Immunofluorescence, Staining, Labeling, Fluorescence

Journal: Cell reports

Article Title: SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis

doi: 10.1016/j.celrep.2021.108758

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: CD309 PE-Vio770 (clone: REA1046) , Miltenyi Biotec , Cat# 130-117-986; RRID:AB_2733181.

Techniques: Recombinant, Chromatin Immunoprecipitation, Control, Expressing, Plasmid Preparation, Software

Journal: Blood Cancer Journal

Article Title: Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model

doi: 10.1038/bcj.2012.12

Figure Lengend Snippet: VEGF-A expression in DLBCL. ( a ) VEGF-A expression of DLBCL cells in the lymph node lesions according to GCB or non-GCB phenotypes. VEGF-A expression was categorized based on the percentage of DLBCL cells stained as follows: ⩾50%, 3+ positive; 30–49%, 2+ positive; 10–29%, 1+ positive; <10%, negative. ( b ) Cases 1, 2, 3 and 4 are representative of VEGF-A negative, 1+, 2+ and 3+ positive categories, respectively. Photomicrographs with hematoxylin and eosin (HE; upper panels) and VEGF-A staining (lower panels) are shown.

Article Snippet: The following monoclonal antibodies (mAbs) were used for flow cytometry: MultiTEST CD3 (clone SK7) FITC/CD16 (B73.1)+CD56 (NCAM 16.2) PE/CD45 (2D1,) PerCP/CD19 (SJ25C1) APC Reagent (BD Biosciences, San Jose, CA, USA), PerCP-conjugated anti-human CD45 mAb (2D1, BD Biosciences), APC-conjugated anti-CD19 mAb (HIB19, BD Biosciences), PE-conjugated anti-CD25 mAb (M-A251, BD Biosciences), PE-conjugated VEGF-R1 mAb (49560, BD Biosciences), PE-conjugated VEGF-R2 mAb (89106, R&D Systems Inc., Minneapolis, MN, USA) and the appropriate isotype control mAbs.

Techniques: Expressing, Staining

Journal: Blood Cancer Journal

Article Title: Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model

doi: 10.1038/bcj.2012.12

Figure Lengend Snippet: VEGF-A, VEGF-R1 and VEGF-R2 expression in DLBCL cell lines. ( a ) Quantitative reverse transcription (RT)-PCR analysis for VEGF-A and VEGF-R1 in eight DLBCL cell lines, and NOG DLBCL cells from the intraperitoneal mass. ( b ) Flow cytometry for VEGF-R1 in DLBCL cell lines, and NOG DLBCL cells from the intraperitoneal mass. ( c ) Bevacizumab has no direct anti-proliferative activity against DLBCL cell lines (OCI-Ly19 and Toledo) expressing both VEGF-A and VEGF-R1 (upper panels), and NOG DLBCL cells (lower panels), in vitro . Each result represents three independent experiments.

Article Snippet: The following monoclonal antibodies (mAbs) were used for flow cytometry: MultiTEST CD3 (clone SK7) FITC/CD16 (B73.1)+CD56 (NCAM 16.2) PE/CD45 (2D1,) PerCP/CD19 (SJ25C1) APC Reagent (BD Biosciences, San Jose, CA, USA), PerCP-conjugated anti-human CD45 mAb (2D1, BD Biosciences), APC-conjugated anti-CD19 mAb (HIB19, BD Biosciences), PE-conjugated anti-CD25 mAb (M-A251, BD Biosciences), PE-conjugated VEGF-R1 mAb (49560, BD Biosciences), PE-conjugated VEGF-R2 mAb (89106, R&D Systems Inc., Minneapolis, MN, USA) and the appropriate isotype control mAbs.

Techniques: Expressing, Reverse Transcription, Reverse Transcription Polymerase Chain Reaction, Flow Cytometry, Activity Assay, In Vitro

Journal: Experimental and Therapeutic Medicine

Article Title: TWEAK promotes endothelial progenitor cell vasculogenesis to alleviate acute myocardial infarction via the Fn14-NF-κB signaling pathway

doi: 10.3892/etm.2018.6703

Figure Lengend Snippet: Phenotypic characterization of cultured EPCs. EPCs exhibited a change toward mesenchymal transformation following transplantation in AMI mice. (A) UEA-1 lectin binding (green) and DiI-acLDL molecular probe uptake (red) were evaluated in early and late EPCs to confirm culture using photomicrographs. (B) EPCs expressed CD34, KDR and CD146, but were negative for CD45 and CD133, as assessed using flow cytometry. (C) Immunofluorescent staining was performed with antibodies against CD31 and α-SMA to detect the differentiation of EPCs labeled with DiD in veins and arteries following transplantation in AMI mice. White triangles indicate the differentiated EPCs. EPCs, EPC, endothelial progenitor cells; AMI, acute myocardial infarction; UEA-1, ulex europaeus agglutinin-1; CD, cluster of differentiation; KDR, kinase domain receptor; SMA, smooth muscle actin.

Article Snippet: Matrigel Matrix, and rat anti-mouse antibodies against fluorescein isothiocyanate (FITC)-conjugated CD34 (cat. no. 553733), phycoerythrin (PE)-conjugated KDR (cat. no. 555308), PE-conjugated CD45 (cat. no. 561087), and PE-conjugated CD146 (cat. no. 562196) were purchased from BD Biosciences (Franklin Lakes, NJ, USA).

Techniques: Cell Culture, Transformation Assay, Transplantation Assay, Binding Assay, Flow Cytometry, Staining, Labeling

Journal: Stem Cell Reports

Article Title: Prostaglandin E 2 Is Required for BMP4-Induced Mesoderm Differentiation of Human Embryonic Stem Cells

doi: 10.1016/j.stemcr.2018.01.024

Figure Lengend Snippet: De Novo Synthesis of PGE 2 Is Required for BMP4-Induced Mesoderm Specification of hESCs (A) Schematic of different induction methods. Indo, indomethacin. (B) qPCR analysis of mesodermal marker gene expression levels in hESCs with BMP4 induction plus DMSO (−Indo) or indomethacin (+Indo) for 48 hr. ∗∗ p < 0.01 compared with −Indo group. n ≥ 3 independent experiments. (C and D) Immunostaining (C) and western blotting (D) analysis for BRA in hESCs with BMP4 induction plus DMSO (−Indo) or indomethacin (+Indo) for 48 hr. Scale bars represent 50 μm. (E) hemato-vascular precursors (HV) marker gene expression levels in hESCs with BMP4 induction plus DMSO (−Indo) or indomethacin (+Indo) for 48 hr and hemato-vascular precursors induction (SFDM + 50 ng/mL VEGF + 50 ng/mL bFGF) for 4 days. ∗ p < 0.05, ∗∗ p < 0.01 compared with −Indo group. n = 3 independent experiments. (F and G) Flow cytometry analysis of the percentage of KDR + CD31 + cells after hemato-vascular induction. ∗ p < 0.05 compared with −Indo group. n = 3 independent experiments. (H) Neuroectoderm (NE) marker gene expression levels in hESCs with BMP4 induction plus DMSO (−Indo) or indomethacin (+Indo) for 48 hr. ∗ p < 0.05 compared with −Indo group. n = 3 independent experiments. (I) qPCR analysis of tissue-specific gene expression levels in different engrafts. ∗ p < 0.05, ∗∗ p < 0.01 compared with −Indo group. n = 3 independent experiments. Error bars indicate SD. See also Figure S2 .

Article Snippet: The antibodies used were as follows: KDR-PE (560494) was from BD Bioscience; CD31-APC (17-0319-42) was from eBioscience.

Techniques: Marker, Expressing, Immunostaining, Western Blot, Flow Cytometry